Advanced search
Publication Cover
Current Medical Research and Opinion Volume 22, 2006 - Issue 1
Submit an article Journal homepage
559
Views
64
CrossRef citations to date
0
Altmetric
Original Article

Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster)

Phil McEwan School of Mathematics, Cardiff University, Cardiff, Wales, UK; Cardiff Research Consortium, Heath Park, Cardiff, Wales, UKCorrespondence[email protected]
,
John R. Peters Department of Medicine, University Hospital of Wales, Cardiff, Wales, UK
,
Klas Bergenheim Department of Health Economics, AstraZeneca, Mölndal, Sweden
&
Craig J. Currie Cardiff Research Consortium, Heath Park, Cardiff, Wales, UK; Department of Medicine, School of Medicine, Cardiff University, Cardiff, Wales, UK
Pages 121-129 | Accepted 10 Nov 2005, Published online: 25 Nov 2005

Citations (64)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (7)

J. Gordon, P. McEwan, U. Sabale, B. Kartman & B. H. R. Wolffenbuttel. (2016) The cost-effectiveness of exenatide twice daily (BID) vs insulin lispro three times daily (TID) as add-on therapy to titrated insulin glargine in patients with type 2 diabetes. Journal of Medical Economics 19:12, pages 1167-1174.
Read now
M. Charokopou, F.J. Sabater, R. Townsend, M. Roudaut, P. McEwan & B.G. Verheggen. (2016) Methods applied in cost-effectiveness models for treatment strategies in type 2 diabetes mellitus and their use in Health Technology Assessments: a systematic review of the literature from 2008 to 2013. Current Medical Research and Opinion 32:2, pages 207-218.
Read now
Shuyan Gu, Jing Deng, Lizheng Shi, Yiming Mu & Hengjin Dong. (2015) Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China. Journal of Medical Economics 18:10, pages 808-820.
Read now
Alexandra Ward, Duygu Bozkaya, Jochen Fleischmann, Dominique Dubois, Rainer Sabatowski & J. Jaime Caro. (2007) Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone. Current Medical Research and Opinion 23:10, pages 2333-2345.
Read now
Louis S. Matza, Nicole Yurgin, Kristina S. Boye, Karen Malley & Jodi M. Shorr. (2007) Obese versus non-obese patients with type 2 diabetes: patient-reported outcomes and utility of weight change. Current Medical Research and Opinion 23:9, pages 2051-2062.
Read now
Craig J. Currie, Christopher Ll. Morgan, Chris D. Poole, Peter Sharplin, Morten Lammert & Phil McEwan. (2006) Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Current Medical Research and Opinion 22:8, pages 1523-1534.
Read now
J. Jaime Caro, Shien Guo, Alexandra Ward, Shajil Chalil, Farzana Malik & Francisco Leyva. (2006) Modelling the economic and health consequences of cardiac resynchronization therapy in the UK. Current Medical Research and Opinion 22:6, pages 1171-1179.
Read now

Articles from other publishers (57)

Centaine L Snoswell, Kathryn J Vitangcol, Helen M Haydon, Leonard C Gray, Floyd Leedie, Anthony C Smith & Liam J Caffery. (2023) Cost-effectiveness of remote patient monitoring for First Nations peoples living with diabetes in regional Australia. Journal of Telemedicine and Telecare 29:10_suppl, pages 3S-7S.
Crossref
Phil McEwan, Volker Foos, Becky Martin, Jieling Chen & Marc Evans. (2023) Estimating the value of sodium‐glucose cotransporter‐2 inhibitors within the context of contemporary guidelines and the totality of evidence . Diabetes, Obesity and Metabolism 25:7, pages 1830-1838.
Crossref
Xinyu Li, Fang Li, Junfeng Wang, Anoukh van Giessen & Talitha L. Feenstra. (2023) Prediction of complications in health economic models of type 2 diabetes: a review of methods used. Acta Diabetologica 60:7, pages 861-879.
Crossref
Marc Evans, Sasha Berry, Avideh Nazeri, Samuel JP Malkin, Donna Ashley, Barnaby Hunt & Stephen C Bain. (2022) The challenges and pitfalls of incorporating evidence from cardiovascular outcomes trials in health economic modelling of type 2 diabetes. Diabetes, Obesity and Metabolism 25:3, pages 639-648.
Crossref
Carlos Escobar, Cristóbal Morales, Margarita Capel, Susana Simón, Ferran Pérez-Alcántara & Elisenda Pomares. (2022) Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study. BMC Health Services Research 22:1.
Crossref
Johannes Pöhlmann, Klas Bergenheim, Juan-Jose Garcia Sanchez, Naveen Rao, Andrew Briggs & Richard F. Pollock. (2022) Modeling Chronic Kidney Disease in Type 2 Diabetes Mellitus: A Systematic Literature Review of Models, Data Sources, and Derivation Cohorts. Diabetes Therapy 13:4, pages 651-677.
Crossref
Elton Mukonda, Susan Cleary & Maia Lesosky. (2021) A review of simulation models for the long-term management of type 2 diabetes in low-and-middle income countries. BMC Health Services Research 21:1.
Crossref
Jiayu Li, Yun Bao, Xuedi Chen & Limin Tian. (2021) Decision models in type 2 diabetes mellitus: A systematic review. Acta Diabetologica 58:11, pages 1451-1469.
Crossref
N. Van der Linden, S. Van Olst, S. Nekeman & C.A. Uyl‐de Groot. (2020) The cost‐effectiveness of dapagliflozin compared to DPP‐4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands. Diabetic Medicine 38:4.
Crossref
Shuyan Gu, Lizheng Shi, Hui Shao, Xiaoyong Wang, Xiaoqian Hu, Yuxuan Gu & Hengjin Dong. (2020) Choice across 10 pharmacologic combination strategies for type 2 diabetes: a cost-effectiveness analysis. BMC Medicine 18:1.
Crossref
Pierre Johansen, Jonas Håkan-Bloch, Aiden R. Liu, Peter G. Bech, Sofie Persson & Lawrence A. Leiter. (2019) Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada. PharmacoEconomics - Open 3:4, pages 537-550.
Crossref
Daniel M. Sugrue, Thomas Ward, Sukhvir Rai, Phil McEwan & Heleen G. M. van Haalen. (2019) Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design. PharmacoEconomics 37:12, pages 1451-1468.
Crossref
Verughese Jacob, Sajal K. Chattopadhyay, David P. Hopkins, Jeffrey A. Reynolds, Ka Zang Xiong, Christopher D. Jones, Betsy J. Rodriguez, Krista K. Proia, Nicolaas P. Pronk, John M. Clymer & Ron Z. Goetzel. (2019) Economics of Community Health Workers for Chronic Disease: Findings From Community Guide Systematic Reviews. American Journal of Preventive Medicine 56:3, pages e95-e106.
Crossref
Mohammad Z.I. Chowdhury, Fahmida Yeasmin, Doreen M. Rabi, Paul E. Ronksley & Tanvir C. Turin. (2019) Prognostic tools for cardiovascular disease in patients with type 2 diabetes: A systematic review and meta-analysis of C-statistics. Journal of Diabetes and its Complications 33:1, pages 98-111.
Crossref
Joan Gil, Antoni Sicras-Mainar & Eugenio Zucchelli. (2017) Uncontrolled diabetes and health care utilisation: panel data evidence from Spain. The European Journal of Health Economics 19:6, pages 785-795.
Crossref
Jennifer Mason Lobo. 2018. Decision Analytics and Optimization in Disease Prevention and Treatment. Decision Analytics and Optimization in Disease Prevention and Treatment 349 365 .
Shuyan Gu, Xiaoyong Wang, Qing Qiao, Weiguo Gao, Jian Wang & Hengjin Dong. (2017) Cost‐effectiveness of exenatide twice daily vs insulin glargine as add‐on therapy to oral antidiabetic agents in patients with type 2 diabetes in China. Diabetes, Obesity and Metabolism 19:12, pages 1688-1697.
Crossref
Sajal K. Chattopadhyay, Verughese Jacob, Shawna L. Mercer, David P. Hopkins, Randy W. Elder & Christopher D. Jones. (2017) Community Guide Cardiovascular Disease Economic Reviews: Tailoring Methods to Ensure Utility of Findings. American Journal of Preventive Medicine 53:6, pages S155-S163.
Crossref
Alexandre Baptista, Inês Teixeira, Sónia Romano, António Vaz Carneiro & Julian Perelman. (2016) The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic review of cost-effectiveness studies. The European Journal of Health Economics 18:8, pages 937-965.
Crossref
Verughese Jacob, Sajal K. Chattopadhyay, Krista K. Proia, David P. Hopkins, Jeffrey Reynolds, Anilkrishna B. Thota, Christopher D. Jones, Daniel T. Lackland, Kimberly J. Rask, Nicolaas P. Pronk, John M. Clymer & Ron Z. Goetzel. (2017) Economics of Self-Measured Blood Pressure Monitoring: A Community Guide Systematic Review. American Journal of Preventive Medicine 53:3, pages e105-e113.
Crossref
Josephine Solowiej-Wedderburn, Mark Ide & Mark Pennington. (2017) Cost-effectiveness of non-surgical periodontal therapy for patients with type 2 diabetes in the UK. Journal of Clinical Periodontology 44:7, pages 700-707.
Crossref
Xinyang Hua, Thomas Wai-Chun Lung, Andrew Palmer, Lei Si, William H. Herman & Philip Clarke. (2016) How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus? a Systematic Review. PharmacoEconomics 35:3, pages 319-329.
Crossref
Shuyan Gu, Yuhang Zeng, Demin Yu, Xiaoqian Hu & Hengjin Dong. (2016) Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China. PLOS ONE 11:11, pages e0167190.
Crossref
Shuyan Gu, Yiming Mu, Suodi Zhai, Yuhang Zeng, Xuemei Zhen & Hengjin Dong. (2016) Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China. PLOS ONE 11:11, pages e0165629.
Crossref
Phil McEwan, Hayley Bennett, Jonathan Fellows, Jennifer Priaulx & Klas Bergenheim. (2016) The Health Economic Value of Changes in Glycaemic Control, Weight and Rates of Hypoglycaemia in Type 1 Diabetes Mellitus. PLOS ONE 11:9, pages e0162441.
Crossref
Lindsay Govan, Olivia Wu, Robert Lindsay & Andrew Briggs. (2015) How Do Diabetes Models Measure Up? A Review of Diabetes Economic Models and ADA Guidelines. Journal of Health Economics and Outcomes Research 3:2, pages 132-152.
Crossref
Philip McEwan, Thomas Ward, Hayley Bennett & Klas Bergenheim. (2015) Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model. Cost Effectiveness and Resource Allocation 13:1.
Crossref
Verughese Jacob, Sajal K. Chattopadhyay, Anilkrishna B. Thota, Krista K. Proia, Gibril Njie, David P. Hopkins, Ramona K.C. Finnie, Nicolaas P. Pronk & Thomas E. Kottke. (2015) Economics of Team-based Care in Controlling Blood Pressure. American Journal of Preventive Medicine 49:5, pages 772-783.
Crossref
Jen Kruger, Daniel Pollard, Hasan Basarir, Praveen Thokala, Debbie Cooke, Marie Clark, Rod Bond, Simon Heller & Alan Brennan. (2015) Incorporating Psychological Predictors of Treatment Response into Health Economic Simulation Models. Medical Decision Making 35:7, pages 872-887.
Crossref
Wen YeMichael BrandleMorton B. BrownWilliam H. Herman. (2015) The Michigan Model for Coronary Heart Disease in Type 2 Diabetes: Development and Validation. Diabetes Technology & Therapeutics 17:10, pages 701-711.
Crossref
Phil McEwanJason GordonMarc EvansThomas WardHayley BennettKlas Bergenheim. (2015) Estimating Cost-Effectiveness in Type 2 Diabetes. Medical Decision Making 35:5, pages 660-670.
Crossref
P. McEwan, H. Bennett, T. Ward & K. Bergenheim. (2014) Refitting of the UKPDS 68 Risk Equations to Contemporary Routine Clinical Practice Data in the UK. PharmacoEconomics 33:2, pages 149-161.
Crossref
Phil McEwan, Volker Foos, James L. Palmer, Mark Lamotte, Adam Lloyd & David Grant. (2014) Validation of the IMS CORE Diabetes Model. Value in Health 17:6, pages 714-724.
Crossref
Amélie Beaudet, John Clegg, Per-Olof Thuresson, Adam Lloyd & Phil McEwan. (2014) Review of Utility Values for Economic Modeling in Type 2 Diabetes. Value in Health 17:4, pages 462-470.
Crossref
Heleen G. M. van Haalen, Marjolein Pompen, Klas Bergenheim, Phil McEwan, Rebecca Townsend & Marina Roudaut. (2013) Cost Effectiveness of Adding Dapagliflozin to Insulin for the Treatment of Type?2 Diabetes Mellitus in the Netherlands. Clinical Drug Investigation 34:2, pages 135-146.
Crossref
Jorge F Elgart, Joaquin E Caporale, Lorena Gonzalez, Eleonora Aiello, Maximiliano Waschbusch & Juan J Gagliardino. (2013) Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina. Health Economics Review 3:1.
Crossref
Mark Pennington, Shelina Visram, Cam Donaldson, Martin White, Monique Lhussier, Katherine Deane, Natalie Forster & Susan M Carr. (2013) Cost-effectiveness of health-related lifestyle advice delivered by peer or lay advisors: synthesis of evidence from a systematic review. Cost Effectiveness and Resource Allocation 11:1.
Crossref
Andrew J. Palmer. (2013) Computer Modeling of Diabetes and Its Complications: A Report on the Fifth Mount Hood Challenge Meeting. Value in Health 16:4, pages 670-685.
Crossref
Ola Granström, Klas Bergenheim, Phil McEwan, Karin Sennfält & Martin Henriksson. (2012) Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden. Primary Care Diabetes 6:2, pages 127-136.
Crossref
Wilma Erhardt, Klas Bergenheim, Isabelle Duprat-Lomon & Phil McEwan. (2012) Cost Effectiveness of Saxagliptin and Metformin versus Sulfonylurea and Metformin in the Treatment of Type 2 Diabetes Mellitus in Germany. Clinical Drug Investigation 32:3, pages 189-202.
Crossref
Jorge F. Elgart, Lorena Gonzalez, Joaquin E. Caporale, Juan E. Valencia & Juan J. Gagliardino. (2012) Economic evaluation of type 2 diabetes treatment with saxagliptin in Colombia. Medwave 12:02, pages e5306-e5306.
Crossref
Lily P.H. Yang. (2012) Saxagliptin. Drugs 72:2, pages 229-248.
Crossref
Wladyslaw GrzeszczakLeszek CzupryniakKatarzyna KolasaCezary SciborskiIsabelle Duprat LomonPhil McEwan. (2012) The Cost-Effectiveness of Saxagliptin Versus NPH Insulin When Used in Combination with Other Oral Antidiabetes Agents in the Treatment of Type 2 Diabetes Mellitus in Poland. Diabetes Technology & Therapeutics 14:1, pages 65-73.
Crossref
Sandra L. Tunis. (2011) Cost Effectiveness of Self-Monitoring of Blood Glucose (SMBG) for Patients with Type 2 Diabetes and Not on Insulin. Applied Health Economics and Health Policy 9:6, pages 351-365.
Crossref
Ana Vieta, Xavier Badia & José A. Sacristán. (2011) A Systematic Review of Patient-Reported and Economic Outcomes: Value to Stakeholders in the Decision-Making Process in Patients With Type 2 Diabetes Mellitus. Clinical Therapeutics 33:9, pages 1225-1245.
Crossref
Alison J. HayesPhilip M. ClarkeMerryn VoyseyAnthony Keech. (2011) Simulation of Quality-Adjusted Survival in Chronic Diseases. Medical Decision Making 31:4, pages 559-570.
Crossref
James G. Xenakis, Elizabeth T. Kinter, K. Jack Ishak, Alexandra J. Ward, Jenő P. Marton, Richard J. Willke, Simon Davies & J. Jaime Caro. (2011) A Discrete-Event Simulation of Smoking-Cessation Strategies Based on Varenicline Pivotal Trial Data. PharmacoEconomics 29:6, pages 497-510.
Crossref
Kristina S. Boye, Louis S. Matza, Kimberly N. Walter, Kate Van Brunt, Andrew C. Palsgrove & Aodan Tynan. (2010) Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. The European Journal of Health Economics 12:3, pages 219-230.
Crossref
A. Patel, E. Maissi, H.-C. Chang, I. Rodrigues, M. Smith, S. Thomas, T. Chalder, U. Schmidt, J. Treasure & K. Ismail. (2011) Motivational enhancement therapy with and without cognitive behaviour therapy for Type 1 diabetes: economic evaluation from a randomized controlled trial. Diabetic Medicine 28:4, pages 470-479.
Crossref
Phil McEwan, Klas Bergenheim, Yong Yuan, Anthony P. Tetlow & Jason P. Gordon. (2010) Assessing the Relationship between Computational Speed and Precision. PharmacoEconomics 28:8, pages 665-674.
Crossref
P. McEwan, M. Evans & K. Bergenheim. (2010) A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes. Diabetes, Obesity and Metabolism 12:7, pages 623-630.
Crossref
P. McEwan, M. Evans, H. Kan & K. Bergenheim. (2010) Understanding the inter‐relationship between improved glycaemic control, hypoglycaemia and weight change within a long‐term economic model. Diabetes, Obesity and Metabolism 12:5, pages 431-436.
Crossref
Shien Guo, Duygu Bozkaya, Alexandra Ward, Judith A. OʼBrien, Khajak Ishak, Randy Bennett, Ahmad Al-Sabbagh & Dennis M. Meletiche. (2009) Treating Relapsing Multiple Sclerosis with Subcutaneous versus Intramuscular Interferon-Beta-1a. PharmacoEconomics 27:1, pages 39-53.
Crossref
Helen L. Walls, Anna Peeters, Christopher M. Reid, Danny Liew & John J. McNeil. (2008) Predicting the Effectiveness of Prevention: A Role for Epidemiological Modeling. The Journal of Primary Prevention 29:4, pages 295-305.
Crossref
Jaro Wex Wechowski. (2008) Cost-Effectiveness of Screening for Pre-Diabetes Among Overweight and Obese U.S. Adults. Diabetes Care 31:5, pages e34-e34.
Crossref
Huseyin Baris Deniz, J Jaime Caro, Alexandra Ward, Jorgen Moller & Farzana Malik. (2008) Economic and health consequences of managing bradycardia with dual-chamber compared to single-chamber ventricular pacemakers in Italy. Journal of Cardiovascular Medicine 9:1, pages 43-50.
Crossref
Louis S. Matza, Kristina S. Boye, Nicole Yurgin, Jessica Brewster-Jordan, Sally Mannix, Jodi M. Shorr & Beth L. Barber. (2007) Utilities and disutilities for type 2 diabetes treatment-related attributes. Quality of Life Research 16:7, pages 1251-1265.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.